Loading
TAC01-CLDN18.2 is an experimental TCR-T cell therapy from Triumvira Immunologics in phase 2 trials, aimed at Claudin 18.2.
TAC01-CLDN18.2 (TAC01) is a TCR-T cell therapy developed by Triumvira Immunologics. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: A genetically engineered autologous T-cell therapy using a T-cell receptor Antigen Coupler (TAC) that directs T cells to CLDN18.2-expressing tumour cells and, once engaged, activates the T cells via the endogenous T-cell receptor. ClinicalTrials.gov describes the intervention as: TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05862324, plans to enrol 113 participants with primary completion expected 2027-08-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A genetically engineered autologous T-cell therapy using a T-cell receptor Antigen Coupler (TAC) that directs T cells to CLDN18.2-expressing tumour cells and, once engaged, activates the T cells via the endogenous T-cell receptor. Connects to Claudin 18.2.
1.TAC01-CLDN18.2 slips into a pocket on Claudin 18.2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TAC01-CLDN18.2" OR ABSTRACT:"TAC01-CLDN18.2" OR TITLE:"TAC01" OR ABSTRACT:"TAC01") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TAC01-CLDN18.2, not a curated reading list.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares TCR-T cell therapy and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.